On Tuesday, Canaccord Genuity (TSX:CF) adjusted its stock price target for Nevro Corp (NYSE:NVRO) to $7.00, down from the previous $8.00, while maintaining a Hold rating on the stock.
The firm's analysis followed Nevro's third-quarter earnings report, which revealed revenues of $96.9 million, a decline of 6.7% year-over-year but surpassing both Canaccord Genuity's and the Street's expectations of $93.7 million and $93.1 million, respectively. Revenue from both the United States and international markets exceeded the firm's forecasts.
The company's adjusted EBITDA for the quarter was notably better than anticipated, coming in at a loss of $1.8 million compared to the expected loss of $9.8 million. This improvement was attributed to effective cost-cutting measures that enhanced operating leverage.
Despite the positive EBITDA performance, Nevro has decided to maintain its revenue guidance for the full year 2024, indicating a potential lower-than-expected revenue for the fourth quarter of 2024.
Nevro's market continues to face challenges, including strong competition from closed-loop technology. To combat this, the company is focusing on artificial intelligence innovations. In September, Nevro received FDA approval for HFX iQ with HFX AdaptivAI, which started a limited market release. AdaptivAI aims to provide more proactive patient care and reduce the need for device charging due to increased efficiency.
The company previously reduced its direct-to-consumer (DTC) marketing efforts to accelerate its path to profitability. However, a 15.2% year-over-year drop in US trial procedures during the third quarter led management to recognize the need for increased DTC spending. The effects of this increased spending are not anticipated to materialize until the second half of 2025.
As Nevro explores strategic options for the business, no specific details have been disclosed. The firm reiterated its Hold rating on Nevro shares, citing the ongoing challenges and competitive pressures in the market.
In other recent news, Nevro Corp has reported its Q3 results and future strategies. Despite a worldwide revenue decrease of 6.7% to $96.9 million and a drop in U.S. spinal cord stimulation trial procedures by 15.2%, the company saw improvements in its net loss from operations and adjusted EBITDA.
Nevro Corp continues to target expansion in the underpenetrated painful diabetic neuropathy (PDN) market, leveraging promising clinical study results. The company has also introduced its AI-driven HFX iQ with HFX AdaptivAI technology and plans to grow its SI joint fusion business, with meaningful contributions expected starting in 2025.
Full-year revenue guidance remains at approximately $400 million to $405 million, reflecting a 5-6% decrease from 2023. Nevro Corp anticipates improved cash flow in Q4 2024 due to restructuring and working capital management. These are some of the recent developments with Nevro Corp.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Nevro Corp's financial situation, aligning with Canaccord Genuity's analysis. The company's market capitalization stands at $198.35 million, reflecting the challenges mentioned in the article. Nevro's revenue for the last twelve months as of Q2 2024 was $426.1 million, with a modest growth of 1.59%. However, the quarterly revenue growth for Q2 2024 showed a decline of 4.27%, consistent with the difficulties outlined in the report.
InvestingPro Tips highlight that Nevro is "quickly burning through cash" and "not profitable over the last twelve months," which explains the company's focus on cost-cutting measures and path to profitability mentioned in the article. The stock's significant decline, with a 45.66% drop in the last six months, underscores the market's concerns about Nevro's performance and competitive pressures.
It's worth noting that despite these challenges, Nevro's liquid assets exceed short-term obligations, potentially providing some financial flexibility as the company navigates its strategic options. For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for Nevro Corp, which could provide valuable insights into the company's future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.